Results from Calprotectin study

01. Oct 2018 | 3 min read

 Moss 01.10.18

Gentian Diagnostics AS is pleased to announce that today the results from a study comparing the levels of the biomarker calprotectin with the biomarkers procalcitonin (PCT) and heparin binding protein (HBP) was published at the International Sepsis Forum in Bangkok.

All adult patients with arterial cannula that where primarily admitted to the mixed ICU at Östersund General Hospital between the 1st of February 2012 and 31st of January 2013 were screened for discharge diagnoses. Plasma taken on admission from patients was analysed for Calprotectin, and the more investigated sepsis biomarkers Heparin Binding Protein (HBP) and Procalcitonin. (HBP) and Procalcitonin. The study compared levels of these biomarkers in patients with sepsis (defined according to Sepsis 2) with levels in patients admitted for trauma, i.e. controls with inflammation, patients with other medical conditions (OMC), i.e. medical admissions with no infection, and finally with medical and surgical patients without these pre-specified diagnoses (Miscellaneous conditions).

328 patients met the inclusion criteria and Calprotectin performed best in discrimination between patients with sepsis and trauma patients and the conclusion from this study is that Calprotectin may be superior to Procalcitonin and HBP in indicating patients with sepsis as calprotectin, unlike HBP and procalcitonin, was consistently higher in sepsis patients compared to patients with other diagnoses with and without systemic inflammation. Calprotectin performed better then PCT and HBP in diagnosis of sepsis and distinguishing between patients with sepsis and trauma patients. Calprotectin and HBP showed predictive ability regarding 30 days mortality. Procalcitonin did not.

Sepsis is the leading cause of death in ICU with a continuously increasing incidence and a high mortality rate. Early treatment improves outcome suggesting that rapid identification of patients with sepsis is important.

The study was conducted in collaboration with Karolinska Institute, Uppsala University and Umeå University.

Please see the enclosed research poster for further information.

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics AS
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics AS
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525

 
MeldingsID:  460418
 

You may also read


Dec 16, 2019 - Kristin Hart

Financial calendar

Financial calendar for Gentian Diagnostics AS

Dec 05, 2019 - Kristin Hart

Gentian Diagnostics presents at DNB conference in New York

Moss 05.12.19 The CEO of Gentian Diagnostics, Dr. Hilja Ibert, will today give a company presentation at the..

Nov 29, 2019 - Kristin Hart

Share capital increase registered

Reference is made to the stock exchange notice from Gentian Diagnostics AS (the "Company") on 25 November..